Mark S. Hixon - Publications, H-index & Citations

Mark S. Hixon

Janssen Pharmaceutica NV

29H指数

116论文数

2.1K被引数

收录论文 50

发表时间

Identification of a novel dependency between PRMT5 and APC-LOF in preclinical models of FAP disease 在FAP疾病预临床模型中鉴定PRMT5与APC-LOF之间的一种新型依赖关系

Communications Biology

IF5.1

2026-10-03

OAAI

Dana Gaffney; Fabian Hulpia; Jan Willem Thuring; Eileen Vesely; Edward Retzbach; Zienab Etwebi; Zhengyu Jiang; Albi Francis; Bethany Mattson; Alexandra Liddane; Kathleen W. Clancy; Froylan Omar Fernandez Candelaria; Yi Fan; Constance Smith-Monroy; Glenn S. Cowley; Victoria Wong; Prashanth Gokare; Sylvia F. Boj; Carla S. Verissimo; Rene Overmeer; Mariana Silva; Gerben ten Hag; Johan Nicolaï; Mark Hixon; Gerald Chu; Andrea DiSandro; Kurtis E. Bachman; David Pocalyko

Discovery of Gut-Restricted PRMT5 Inhibitors to Intercept Colorectal Cancer in Patients with Genetic Loss of Tumor Suppressor Adenomatous Polyposis Coli Hulpia, F.; Schepens, W.; Lepri, S.; Nicolai, J.; Jiang, Z.; Boj, S.F.; Bush, T.L.; Carvalho, M.A.; Chen, F.; Chu, G.; 等. 发现肠道特异性的PRMT5抑制剂，以阻断具有腺瘤性息肉病 coli基因缺失的肿瘤抑制基因患者的结直肠癌。J. Med. Chem. 2025. [Google Scholar] [CrossRef] [PubMed]

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2025-08-01

PREAI

Hulpia, Fabian; Schepens, Wim; Lepri, Susan; Nicolai, Johan; Jiang, Zhengyu; Boj, Sylvia F.; Bush, Tammy L.; Carvalho, Mary-ambre; Chen, Falian; Chu, Gerald; Clancy, Kathleen W.; Etwebi, Zienab; Everaerts, Melissa; Fan, Yi; Fernandez Candelaria, Froylan Omar; Francis, Albi; Hixon, Mark S.; Jardi, Ferran; Jin, Shuai; Larin, Egor M.; Last, Stefaan; Leenaerts, Joseph E.; Li, Siyu; Liddane, Alexandra G.; Lutter, Ferdinand H.; Lv, Dan; Mattson, Bethany; Milligan, Cynthia M.; Patrick, Aaron N.; Patwardhan, Gauri Anand; Perez-Benito, Laura; Pieters, Serge; Renders, Evelien; Retzbach, Ed; Smith-Monroy, Constance; Silva, Jose; Silva, Mariana; Sterckx, Hans; ten Hag, Gerben; Thate, Claudia; Van Brandt, Sven; Verissimo, Carla S.; Verniest, Guido; Vesely, Eileen; Vetrano, Irene; Vinken, Petra; Wang, Yufei; Wong, Victoria; Yao, Xuemei; Yang, Jie; Zijlmans, Remco; Bachman, Kurtis E.; Pocalyko, David; Jimenez, Juan-Miguel; Gaffney, Dana; Thuring, Jan Willem

PET clinical study of novel antipsychotic LB-102 demonstrates unexpectedly prolonged dopamine receptor target engagement

NEUROPSYCHOPHARMACOLOGY

IF7.1

2024-10-16

OAAI

Wong, Dean F.; Chand, Ganesh B.; Caito, Nicole; Eramo, Anna; Grattan, Vincent T.; Hixon, Mark S.; Nicol, Ginger; Lessie, Erin; Prensky, Zachary; Kuwabara, Hiroto; Tian, Lucy; Valenta, Ines; Schindler, Thomas H.; Gruender, Gerhard; Vaino, Andrew R.

A randomized, double-blind, placebo controlled, phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of LB-102, a selective dopamine D2/3/5-HT7 inhibitor

PSYCHOPHARMACOLOGY

IF3.3

2022-07-16

PREAI

Biernat, Lukasz; Grattan, Vincent T.; Hixon, Mark S.; Prensky, Zachary; Vaino, Andrew R.

Integrated Quantum Mechanical and Machine Learning Methods Enable Scalable and General pKa Prediction for Pharmacokinetic Modeling

FASEB JOURNAL

IF4.2

2022-05-13

PREAI

Walden, Daniel M.; Bundey, Yogesh; Brunk, Nicholas E.; Khotimehenko, Maksim; Hou, Hypatia; Chakravarty, Kaushik; Hixon, Mark S.; Varshney, Jyotika

In Silico Development of Combinatorial Therapeutic Approaches Targeting Key Signaling Pathways in Metabolic Syndrome

PHARMACEUTICAL RESEARCH

IF4.3

2022-03-21

PREAI

Khotimchenko, Maksim; Brunk, Nicholas E.; Hixon, Mark S.; Walden, Daniel M.; Hou, Hypatia; Chakravarty, Kaushik; Varshney, Jyotika

Identification of Slow-Binding Inhibitors of the BoNT/A Protease

ACS MEDICINAL CHEMISTRY LETTERS

IF4

2022-03-08

OAAI

Patel, Ealin N.; Turner, Lewis D.; Hixon, Mark S.; Janda, Kim D.

LB-102 displays superior dopamine receptor occupancy compared to amisulpride in mouse and human PET studies

EUROPEAN NEUROPSYCHOPHARMACOLOGY

IF6.7

2021-12-01

PREAI

Vaino, A.; Mintz, A.; Eramo, A.; Caito, N.; Chand, G.; Nicol, G.; Hixon, M.; Grattan, V.; Prensky, Z.; Molotkov, A.; Dolan, M.; Oya, S.; Cabrera, M.; Wang, L.; Wong, D.

Discovery of the Bruton's Tyrosine Kinase Inhibitor Clinical Candidate TAK-020 (S)-5-(1-((1-Acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-2,4-dihydro-3H-1,2,4-triazol-3-one, by Fragment-Based Drug Design (vol 64, pg 12893, 2021)

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2021-10-28

OAAI

Sabat, Mark; Dougan, Douglas R.; Ermolieff, Jacques; Halkowycz, Petro; Knight, Beverly; Lawson, J. David; Scorah, Nicholas; Smith, Christopher R.; Taylor, Ewan R.; Vu, Phong; Wyrick, Corey; Wang, Haixia; Balakrishna, Deepika; Hixon, Mark; Madakamutil, Loui; McConn, Donavon

Synthetic fluorescent MYC probe: Inhibitor binding site elucidation and development of a high-throughput screening assay

BIOORGANIC & MEDICINAL CHEMISTRY

IF3

2021-07-01

OAAI

Shirey, Ryan J.; Hart, Jonathan R.; Sridharan, BanuPriya; Novick, Scott J.; Turner, Lewis D.; Zhou, Bin; Nielsen, Alexander L.; Eubanks, Lisa M.; Ueno, Lynn; Hixon, Mark S.; Lairson, Luke L.; Spicer, Timothy P.; Scampavia, Louis D.; Griffin, Patrick R.; Vogt, Peter K.; Janda, Kim D.

Safety, pharmacokinetics, and pharmacodynamics of LB-102, a selective D2/5-P.467HT7 antagonist, in healthy volunteers

EUROPEAN NEUROPSYCHOPHARMACOLOGY

IF6.7

2020-11-01

PREAI

Vaino, A.; Grattan, V. T.; Prensky, Z.; Hixon, M. S.; Biernat, L.

Salicylanilide Analog Minimizes Relapse of Clostridioides difficile Infection in Mice

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2020-06-02

PREAI

Blake, Steven; Thanissery, Rajani; Rivera, Alissa J.; Hixon, Mark S.; Lin, Mingliang; Theriot, Casey M.; Janda, Kim D.

Building a translational bridge from animals to man for clinical candidate lb-102, a next-generation benzamide antipsychotic

EUROPEAN NEUROPSYCHOPHARMACOLOGY

IF6.7

2019-12-01

PREAI

Vaino, A.; Grattan, V.; Prensky, Z.; Hixon, M.

Antipsychotic Benzamides Amisulpride and LB-102 Display Polypharmacy as Racemates, S Enantiomers Engage Receptors D2 and D3, while R Enantiomers Engage 5-HT7

ACS OMEGA

IF4.3

2019-08-15

OAAI

Grattan, Vincent; Vaino, Andrew R.; Prensky, Zachary; Hixon, Mark S.

Monoclonal Antibodies for Combating Synthetic Opioid Intoxication

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

IF15.6

2019-06-12

OAAI

Smith, Lauren C.; Bremer, Paul T.; Hwang, Candy S.; Zhou, Bin; Ellis, Beverly; Hixon, Mark S.; Janda, Kim D.

LB-102, a potential schizophrenia treatment, displays polypharmacology as a racemate - S enantiomer binds D2 and D3 and R binds 5-Ht7

EUROPEAN NEUROPSYCHOPHARMACOLOGY

IF6.7

2019-01-01

PREAI

Vaino, A.; Prensky, Z.; Hixon, M.; Grattan, V.

Noninvasive Urine Biomarker Lateral Flow Immunoassay for Monitoring Active Onchocerciasis

ACS INFECTIOUS DISEASES

IF3.8

2018-08-24

OAAI

Shirey, Ryan J.; Globisch, Daniel; Eubanks, Lisa M.; Hixon, Mark S.; Janda, Kim D.

Synthetic molecules for disruption of the MYC protein-protein interface

BIOORGANIC & MEDICINAL CHEMISTRY

IF3

2018-08-01

OAAI

Jacob, Nicholas T.; Miranda, Pedro O.; Shirey, Ryan J.; Gautam, Ritika; Zhou, Bin; Izquierdo, M. Elena de Orbe; Hixon, Mark S.; Hart, Jonathan R.; Ueno, Lynn; Vogt, Peter K.; Janda, Kim D.

Pre-clinical evaluation of two novel benzamides, LB-102 and 103, for the treatment of schizophrenia

EUROPEAN NEUROPSYCHOPHARMACOLOGY

IF6.7

2017-10-01

PREAI

Neill, J.; Grayson, B.; Podda, G.; Cadinu, D.; Beconi, M.; Grattan, V.; Hixon, M. S.; Prensky, Z.; Vaino, A.

MET Tyrosine Kinase Inhibition Enhances the Antitumor Efficacy of an HGF Antibody

MOLECULAR CANCER THERAPEUTICS

IF5.5

2017-07-04

OAAI

Farrell, Pamela J.; Matuszkiewicz, Jennifer; Balakrishna, Deepika; Pandya, Shweta; Hixon, Mark S.; Kamran, Ruhi; Chu, Shaosong; Lawson, J. David; Okada, Kengo; Hori, Akira; Mizutani, Akio; Iwata, Hidehisa; de Jong, Ron; Hibner, Barbara; Vincent, Patrick

研究方向